Cited by

• Glutathione depletion increases the cytotoxicity of melphalan to PC-3, an androgen-insensitive prostate cancer cell line.

  Canada A, Herman L, Kidd K, Robertson C, Trump D. Canada A, et al. Cancer Chemother Pharmacol. 1993;32(1):73-7. doi: 10.1007/BF00685880. Cancer Chemother Pharmacol. 1993. PMID: 8462127
• Etoposide, epirubicin and carboplatin in hormone-refractory prostate cancer.

  Fuse H, Muraishi Y, Fujishiro Y, Katayama T. Fuse H, et al. Int Urol Nephrol. 1996;28(1):79-85. doi: 10.1007/BF02550142. Int Urol Nephrol. 1996. PMID: 8738624
• Effect of androgen blockade on HER-2 and matrix metalloproteinase-2 expression on bone marrow micrometastasis and stromal cells in men with prostate cancer.

  Murray NP, Reyes E, Badinez L, Orellana N, Fuentealba C, Olivares R, Porcell J, Dueñas R. Murray NP, et al. ScientificWorldJournal. 2013 May 14;2013:281291. doi: 10.1155/2013/281291. Print 2013. ScientificWorldJournal. 2013. PMID: 23766685 Free PMC article. Clinical Trial.
• Immunotherapy for Prostate Cancer with Gc Protein-Derived Macrophage-Activating Factor, GcMAF.

  Yamamoto N, Suyama H, Yamamoto N. Yamamoto N, et al. Transl Oncol. 2008 Jul;1(2):65-72. doi: 10.1593/tlo.08106. Transl Oncol. 2008. PMID: 18633461 Free PMC article.
• Correlation of vascular endothelial growth factor expression with fibroblast growth factor-8 expression and clinico-pathologic parameters in human prostate cancer.

  West AF, O'Donnell M, Charlton RG, Neal DE, Leung HY. West AF, et al. Br J Cancer. 2001 Aug 17;85(4):576-83. doi: 10.1054/bjoc.2001.1971. Br J Cancer. 2001. PMID: 11506499 Free PMC article.